scholarly journals “It's been a life‐changing experience!” A qualitative study of young adult cancer survivors’ experiences of the coexistence of negative and positive outcomes after cancer treatment

2019 ◽  
Vol 60 (6) ◽  
pp. 577-584
Author(s):  
May A. Hauken ◽  
Marthe Grue ◽  
Atle Dyregrov
2018 ◽  
Vol 7 (1) ◽  
pp. 88-96 ◽  
Author(s):  
Elizabeth A. May ◽  
Brittany C. McGill ◽  
Eden G. Robertson ◽  
Antoinette Anazodo ◽  
Claire E. Wakefield ◽  
...  

2020 ◽  
Vol 9 (3) ◽  
pp. 410-417 ◽  
Author(s):  
Evelina M. Miropolsky ◽  
Kevin Scott Baker ◽  
Mark Abbey-Lambertz ◽  
Karen Syrjala ◽  
Eric J. Chow ◽  
...  

Author(s):  
Alexa C O Medica ◽  
Brian W Whitcomb ◽  
Ksenya Shliakhsitsava ◽  
Andrew C Dietz ◽  
Kelsey Pinson ◽  
...  

Abstract Context Although stages of reproductive aging for women in the general population are well described by STRAW+10 criteria, this is largely unknown for female adolescent and young adult cancer survivors (AYA survivors). Objective This work aimed to evaluate applying STRAW + 10 criteria in AYA survivors using bleeding patterns with and without endocrine biomarkers, and to assess how cancer treatment gonadotoxicity is related to reproductive aging stage. Design The sample (n = 338) included AYA survivors from the Reproductive Window Study cohort. Menstrual bleeding data and dried-blood spots for antimüllerian hormone (AMH) and follicle-stimulating hormone (FSH) measurements (Ansh DBS enzyme-linked immunosorbent assays) were used for reproductive aging stage assessment. Cancer treatment data were abstracted from medical records. Results Among participants, mean age 34.0 ± 4.5 years and at a mean of 6.9 ± 4.6 years since cancer treatment, the most common cancers were lymphomas (31%), breast (23%), and thyroid (17%). Twenty-nine percent were unclassifiable by STRAW + 10 criteria, occurring more frequently in the first 2 years from treatment. Most unclassifiable survivors exhibited bleeding patterns consistent with the menopausal transition, but had reproductive phase AMH and/or FSH levels. For classifiable survivors (48% peak reproductive, 30% late reproductive, 12% early transition, 3% late transition, and 7% postmenopause), endocrine biomarkers distinguished among peak, early, and late stages within the reproductive and transition phases. Gonadotoxic treatments were associated with more advanced stages. Conclusions We demonstrate a novel association between gonadotoxic treatments and advanced stages of reproductive aging. Without endocrine biomarkers, bleeding pattern alone can misclassify AYA survivors into more or less advanced stages. Moreover, a large proportion of AYA survivors exhibited combinations of endocrine biomarkers and bleeding patterns that do not fit the STRAW + 10 criteria, suggesting the need for modified staging for this population.


Sign in / Sign up

Export Citation Format

Share Document